Navigation Links
Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Date:4/9/2013

BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with Genentech/Novartis's Xolair, the only approved drug that serves this population. However, by the end of 2018, when three novel biologics and biosimilar versions of Xolair are expected to be available, surveyed pulmonologists estimate that nearly 50 percent of their severe, refractory patients will be treated. This response demonstrates the great unmet need for this population that will be at least partially filled by the emerging biologics.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The new U.S. Physician & Payer Forum report entitled How Will U.S. Physician and Payer Attitudes and Decisions Shape the Asthma Market for Patients with Severe, Refractory Disease? also finds that most surveyed pulmonologists are receptive to prescribing biosimilar versions of Xolair in their first year of availability and intend to prescribe Boehringer Ingelheim/Pfizer's Spiriva upon its approval for asthma. As a result, these prescribing habits could delay prescribing of branded biologics to a later line of therapy.

The report also finds that surveyed managed care organization (MCO) pharmacy and medical directors' expected formulary tier positions of emerging biologics depend on price more so than potential Phase III clinical trial results, suggesting that price point is important for ensuring favorable formulary coverage despite the unmet need for additional treatment options for severe, refractory asthma.

"Surveyed payers indicated that the most com
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
7. ChromaDex® Experiencing Higher Than Expected Demand For Its Recently Launched BluScience™ Line of Dietary Supplements
8. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
9. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
10. Asthma and COPD Drug Market Expected to Reach USD 26,965.5 Million Globally in 2017: Transparency Market Research
11. Medical Alarm Lands European Order with Additional Orders Expected
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... 31, 2015.  The net loss and the loss from ... $13.0 million, respectively, compared to $10.7 million and $8.8 ... March 31, 2015, Alexza had consolidated cash, cash equivalents, ... "We continue to focus on ways in which ...
(Date:5/6/2015)... NEW YORK , May 6, 2015 /PRNewswire/ ... patient activation and patient-reported outcomes for chronic pain, ... report released by The Bravewell Collaborative ... by the Patients Receiving Integrative Medicine Interventions Effectiveness ... medicine. Using data from PRIMIER ...
(Date:5/6/2015)... , May 6, 2015 CVS Health (NYSE: CVS ... Baltimore locations that sustained heavy fire damage during ... in Baltimore over the past week or ... is ahead," said CVS Health President and CEO Larry Merlo ... path to better health. There is no better way that we ...
Breaking Medicine Technology:Alexza Reports 2015 First Quarter Financial Results 2Alexza Reports 2015 First Quarter Financial Results 3Alexza Reports 2015 First Quarter Financial Results 4Alexza Reports 2015 First Quarter Financial Results 5Alexza Reports 2015 First Quarter Financial Results 6Alexza Reports 2015 First Quarter Financial Results 7Alexza Reports 2015 First Quarter Financial Results 8Alexza Reports 2015 First Quarter Financial Results 9Alexza Reports 2015 First Quarter Financial Results 10Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression 2CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2
(Date:5/6/2015)... Animals make just as good friends as they do ... health. An Ohio veterinarian has been observing this ... health advantages of owning a pet. , “When animals and ... ownership, there are proven health benefits for people-- including physical, ... the Animal Medical Center of Streetsboro said. Every ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Inversion ... specializes in yoga and Pilates classes, provides personalized ... and products, starting with its new Pilates Ring ... effort of becoming leaner, stronger, more centered and ... offer a fresh venue to healthy fitness through ...
(Date:5/6/2015)... MA (PRWEB) May 06, 2015 ... for healthcare professionals and students, announced today that in ... 94% confirmed that use of the clinical decision support ... by the end of 2014, UpToDate users in more ... clinical topics per month, on average. In Germany alone, ...
(Date:5/6/2015)... Beverly Hills, California (PRWEB) May 06, 2015 ... honor of presenting at the 8th Milano Masterclass. As ... the world’s most elite plastic surgeons. Dr. Batniji was ... Academy of Facial Plastic and Reconstructive Surgery, Dr. Pietro Palma. ... year in Milan, Italy. The conference hosts a diverse, ...
(Date:5/6/2015)... WASHINGTON, DC (PRWEB) May 06, 2015 ... international organization representing the regenerative medicine and advanced ... first-ever quarterly data report, offering an in-depth look ... January through March 2015. , The report is ... standalone graphics highlighting key data points, available ...
Breaking Medicine News(10 mins):Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3
... project supported by Genome BC, a Vancouver pediatric pathologist ... leading the team that will explore the genomes (DNA) ... Dr. Poul Sorensen and his colleagues in the Canadian ... between primary and metastatic tumours using revolutionary genomics technology ...
... the Breast Cancer Initiative, as the project is ... the Swedish innovation agency Vinnova. The project is ... where immunologists, tumour biologists, nanotechnologists, bioinformaticians and cancer ... that our research can benefit patients earlier", comments ...
... happy? Smile at your customers. Want to keep yourself happy ... study led by a Michigan State University business scholar suggests ... mood and withdraw from work, affecting productivity. But workers who ... as a tropical vacation or a child,s recital improve ...
... medical literature on cannabis use and sexual health has ... performance. "Cannabis is the most widely-used illicit drug ... Department of Pharmacology and Toxicology. "It is also often ... of the hazardous effects it may be having on ...
... of the blood clot-inhibiting medication tifacogin does not appear ... (sCAP), according to a study conducted by researchers from ... drug had shown some potential benefit in the sCAP ... The findings were published online ahead of the print ...
... does it take to keep children active when they get ... in terms of parks and playgrounds has a lot to ... between the quality of outdoor public spaces, parents, perception of ... from the Centre for Physical Activity and Nutrition Research at ...
Cached Medicine News:Health News:New genomics research investigates metastatic childhood cancers 2Health News:Novel methods for improved breast cancer survival 2Health News:Study: For a better workday, smile like you mean it 2Health News:Anti-clotting agent does not improve outcomes of patients with severe pneumonia 2Health News:Anti-clotting agent does not improve outcomes of patients with severe pneumonia 3Health News:Poor park planning drives kids indoors 2
This family of punches offers the best of both worlds the lowest profile and the largest bite, facilitating end-on and lateral cutting the most versatile instrument available....
ACUFEX Loop Handle. Blunt nose basket punch enables flush contouring of meniscus....
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
Medicine Products: